Deschatelets Pascal

CIK 00016577201 companyWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001657720

Recent Transactions

50 trades

Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-22$21.77/sh−5,928→ 1,151,382 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-20$19.79/sh−909→ 1,157,310 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-06-09$19.39/sh+82,500→ 82,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-05-21−12,780→ 0 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-05-21$3.76/sh+12,780→ 1,160,496 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-29$29.52/sh−826→ 1,147,716 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-22$30.43/sh−3,948→ 1,148,542 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-21+15,045→ 1,152,490 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-17$29.96/sh−750→ 1,137,445 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-13$28.70/sh−2,288→ 1,138,195 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-05-20$3.76/sh+24,500→ 1,140,483 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-05-20−24,500→ 12,780 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-05-08$4.31/sh+78,907→ 1,194,890 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-05-08$42.15/sh−56,335→ 1,138,555 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-05-08−78,907→ 108,622 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-05-08$42.85/sh−22,472→ 1,116,083 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-05-08$44.02/sh−100→ 1,115,983 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-04-08$54.92/sh−4,728→ 1,115,983 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-04-08$3.76/sh+69,107→ 1,185,090 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-04-08−69,107→ 37,280 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-04-08$54.12/sh−64,379→ 1,120,711 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-08$3.67/sh+69,107→ 1,185,090 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-08$61.88/sh−42,750→ 1,142,340 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-08$62.69/sh−26,257→ 1,116,083 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-03-08−69,107→ 106,387 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-08$63.35/sh−100→ 1,115,983 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-02-12$67.77/sh−1,148→ 1,115,983 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-29$64.14/sh−874→ 1,117,131 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-22$65.00/sh−3,913→ 1,118,005 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16+6,743→ 1,123,550 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-16$66.30/sh+9,805→ 9,805 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16$66.81/sh−1,632→ 1,121,918 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-14$3.76/sh+45,000→ 1,116,807 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-11-14−45,000→ 175,494 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-08$2.67/sh+17,494→ 1,083,807 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-11-08−17,494→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-08$47.27/sh−12,000→ 1,071,807 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-10-09−18,500→ 17,494 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-09$40.38/sh−12,000→ 1,066,313 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-09$2.67/sh+18,500→ 1,078,313 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-08$42.87/sh−12,000→ 1,059,813 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-08$2.67/sh+18,500→ 1,071,813 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-09-08−18,500→ 35,994 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-08-08$2.67/sh+18,500→ 1,065,313 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-08-08−18,500→ 54,494 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-08-08$23.66/sh−12,000→ 1,053,313 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-10$84.55/sh−12,000→ 1,046,813 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-07-10−18,500→ 72,994 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-07-10$2.67/sh+18,500→ 1,058,813 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-06-08$91.35/sh−12,000→ 1,040,313 total

Companies

Apellis Pharmaceuticals, Inc.
Chief Scientific Officer
$APLS

Recent Filings

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov